Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.
With a major new HIV vaccine trial under way, cautious optimism is stirring that the vaccine will prove effective enough for a rollout.
The major trial compared those starting HIV treatment immediately and those waiting till their CD4 counts dropped below 200.
UNAIDS sounds the alarm about this troubling shift in a once hopeful trend.
Even though higher proportions of those making later clinic visits reported more recent condomless sex, the whole group is still HIV free.
8 HIV/AIDS groups launched the initiative. Now you can read, sign and share it.
Among young men on Truvada as PrEP, bone loss stabilizes after first year and reverses after stopping.
Just 4 percent of children born to HIV-positive mothers contract the virus by 18 months of age.
A roundup of the major presentations on HIV science at the international conference held July 22 to 28 outlines many exciting developments.
The cure rate for Gilead’s new treatment is comparable to what has been seen in people who have only hep C.
A new study examines factors that predicted which black men who have sex with men (MSM) would better stick with the daily Truvada regimen.
See what happens when people affected by HIV gain access to treatment.
The Phase IIb/III HVTN 702 trial will begin enrollment in southern Africa in the fall.
But will there be enough money to keep pushing the dial?
The final results of the HPTN 052 study of mixed-HIV-status, opposite-sex partners are in.
Constantly adapting the way that the response tries to reach young people is key.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.